基于活检的最小侵入性诊断以支持精确的癌症医学
Bo Franzén1,2, Gert Auer1, Rolf Lewensohn1,3
1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Molecular oncology
|March 23, 2024
概括
细针吸收活检 (FNA) 分子细胞学为实体瘤诊断提供了核心针活检的患者友好的替代方案. 这种微侵袭性技术有助于适应性治疗决策和瘤微环境的表征.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 分子诊断学 分子诊断
背景情况:
- 针对固体瘤的精密癌症医学 (PCM) 需要最少的侵入性诊断技术.
- 目前的诊断方法,如核心针活检 (CNB) 可能是创伤性的,并导致并发症.
研究的目的:
- 描述基于细针吸收活检 (FNA) 的分子细胞学的发展和倡导的实施.
- 将FNA分子细胞学作为瘤采样中CNB的患者友好和有效替代品.
主要方法:
- 开发基于FNA的分子细胞学技术.
- 超敏感分子方法与图像引导FNA的整合.
- 使用FNA样本对瘤微环境的表征.
主要成果:
- FNA分子细胞学显示,在各种瘤类型中,有很大的潜力可以替代CNB.
- 使用分子方法的图像引导FNA使瘤微环境的表征成为可能.
- FNA的可重复性有助于定期采样以进行适应性治疗.
结论:
- 基于分子FNA的采样是一种患者友好的诊断方法,有可能取代CNB.
- 这种技术支持明智的治疗决策,缩短医疗服务的交付时间,并提供经济效益.
- 建议增加分子FNA的实施,以改善癌症治疗和诊断.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


